Pharmaceutical Technology

AUGUST 9, 2024

For an upfront payment of $700m, MSD will gain access to the CD3 and CD19-targeting bispecific antibody CN201.

Antibody 130

Antibody Marketing 130

Pharmaceutical Technology

SEPTEMBER 27, 2024

The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market.

FDA Approval 162

FDA Approval Marketing Antibody Drugs 162

Bio Pharma Dive

OCTOBER 26, 2022

The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease. It joins a group of medicines on market that target a protein called BCMA.

Protein 290

Protein Antibody Medicine Drugs 290

Bio Pharma Dive

MARCH 23, 2023

The two companies gained billions of dollars in market value after their antibody drug succeeded against a disease that’s been difficult to treat with biologic medicines.

Antibody 286

Antibody Trials Medicine Marketing 286

Bio Pharma Dive

SEPTEMBER 21, 2021

Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019.

FDA Approval 285

FDA Approval Drugs Antibody Medicine 285

Bio Pharma Dive

MAY 5, 2021

The privately held biotech believes its drug might treat or prevent infections from existing variants and future coronavirus strains, which could make it a competitor to marketed therapies from Regeneron and Eli Lilly.

Antibody 220

Antibody Marketing Drugs 220

Pharmaceutical Technology

NOVEMBER 27, 2022

Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.

Antibody 130

Antibody Licensing Licensing Development 130

Pharmaceutical Technology

FEBRUARY 8, 2023

The top 20 companies in the global biopharma industry saw 5.4%* aggregate market capitalization from $3.43 Pfizer maintained its third-place position in the market in 2022, reporting a market capitalization of $287.6 witnessed the biggest market capitalization growth of 45.3% trillion to $3.61 billion on Dec 31, 2022.

Marketing 195

Marketing Sales Vaccine Vaccination 195

Pharmaceutical Technology

SEPTEMBER 22, 2022

Abpro has entered a strategic collaboration with Celltrion for the global development and commercialisation of the former's antibody therapy, a t-cell engager known as ABP 102. According to preliminary data, the antibody has demonstrated enhanced efficacy and reduced toxicity versus other treatments for HER2+ cancer indication. .

Antibody 130

Antibody Development Bioinformatics In-Vitro 130

XTalks

JANUARY 21, 2025

The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate (ADC) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer, developed through a global collaboration between Daiichi Sankyo and AstraZeneca. The FDA approval sent Daiichi Sankyos shares soaring by 8.7%

Antibody 105

Antibody FDA Approval HR Trials 105

Pharmaceutical Technology

AUGUST 29, 2022

Sanyou Biopharmaceuticals and Shanghai KangaBio have signed a licencing agreement to expedite the development and innovation of the former’s monoclonal antibody drug. The latest deal will grant KangaBio an exclusive licence for the use of the antibody to carry out research, development, production and marketing of immunotherapy products.

Antibody 130

Antibody Development Drugs Production 130

Pharmaceutical Technology

OCTOBER 19, 2022

Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. . Eucure will oversee the production and delivery of the drug, while Syncromune will handle the clinical development and marketing.

Antibody 130

Antibody Licensing Licensing Containment 130

World of DTC Marketing

MARCH 16, 2021

IN BRIEF: As a marketer, most of us, like a Jungian archetype, are true Communicators. As a pharma marketer who has worked in many other therapeutic categories and recently on a Covid launch, I have become acutely aware of the interaction between national poles and the on-the-ground sentiment I have observed.

Marketing 180

Marketing Vaccine Vaccination RNA 180

Pharmaceutical Technology

OCTOBER 30, 2023

Helinus will receive €42m upfront and will be in line to receive up to €143m in regulatory and sales-based milestone payments.

Licensing 147

Licensing Licensing Antibody Marketing 147

pharmaphorum

SEPTEMBER 30, 2020

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market.

Antibody 135

Antibody Immune Response Trials Protein 135

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.

Development 264

Development Antibody Immune Response Production 264

Pharmaceutical Technology

JANUARY 23, 2023

Disc Medicine has entered an exclusive licence agreement with Mabwell Therapeutics for the latter’s new Anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibodies to modulate iron homeostasis.

Antibody 130

Antibody Medicine Development Drugs 130

pharmaphorum

MARCH 25, 2024

FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma

Antibody 111

Antibody Marketing 111

Pharmaceutical Technology

OCTOBER 12, 2022

Biotech start-up Toregem BioPharma has signed a memorandum of understanding (MoU) with WuXi Biologics to develop the monoclonal antibody, TRG035. Additionally, WuXi Biologics will help the company with the development of the anti-USAG-1 antibody for Investigational New Drug (IND) application.

Antibody 130

Antibody Development Bioassay Manufacturing 130

pharmaphorum

AUGUST 12, 2022

Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld. One group of Chinese researchers has reported however that BA.4

Antibody 145

Antibody Vaccine Vaccination Drugs 145

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The post LegoChem, Amgen partner to develop antibody drug conjugates appeared first on Pharmaceutical Technology.

Antibody 130

Antibody Development Drugs Licensing 130

Pharmaceutical Technology

JANUARY 18, 2023

The National Medical Products Administration (NMPA) of China has approved Shanghai Henlius Biotech ’s monoclonal antibody Hansizhuang (serplulimab injection) along with carboplatin and etoposide to treat extensive stage small cell lung cancer (ES-SCLC). Hansizhuang is the company’s first self-developed anti-PD-1 monoclonal antibody (mAb).

Antibody 130

Antibody Drugs Production Marketing 130

Pharmaceutical Technology

JANUARY 20, 2025

The Prolium deal highlights the growing trend of China-derived experimental therapies entering the US market.

Antibody 147

Antibody Marketing 147

Pharmaceutical Technology

JUNE 20, 2023

In a Phase III clinical trial, SKYCovione showed neutralising antibody responses against the SARS-CoV-2 parental strain. Last month, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted marketing authorisation for SKYCovione to prevent Covid-19 resulting from SARS-CoV-2 infection in people aged 18 years and above.

Vaccine 363

Vaccine Vaccination Protein Clinical Trials 363

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Monoclonal antibody conjugates for cancer treatment.

Antibody 130

Antibody Drugs Development Medicine 130

pharmaphorum

OCTOBER 25, 2021

Novartis isn’t giving up on the programme yet, as it still has other trials of canakinumab in play, but the latest failure makes prospects for the antibody in oncology look increasingly remote. The post Strike two for Novartis’ lung cancer antibody canakinumab appeared first on.

Antibody 124

Antibody Trials Branding Protein 124

Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. It was granted based on data from the Phase III study, which demonstrated that the vaccine induced neutralising antibodies against the SARS-CoV-2 original strain.

Vaccine 298

Vaccine Vaccination Protein Medicine 298

XTalks

FEBRUARY 21, 2025

Antibody-drug conjugates (ADCs) have emerged as one of the most promising advancements in precision oncology, combining targeted delivery with the potency of traditional chemotherapies. Over the last decade, ADCs have gained significant traction, with more therapies being approved and a rapidly expanding development pipeline.

Antibody 52

Antibody Drugs Development Research 52

Pharmaceutical Technology

MARCH 16, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for argenx’s Vyvgart (efgartigimod alfa-fcab) to treat generalised myasthenia gravis (gMG). It attaches to the neonatal Fc receptor (FcRn) that results in circulating immunoglobulin G (IgG) autoantibodies reduction.

Marketing 130

Marketing Antibody Trials Medicine 130

Bio Pharma Dive

MAY 24, 2021

One month after Lilly's first coronavirus antibody was pulled from market, the U.S. government stopped distributing its other treatment in two states.

Antibody 189

Antibody Drugs Marketing 189

Pharmaceutical Technology

APRIL 10, 2023

Evusheld (formerly AZD7442) is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061). The long-acting antibodies are obtained from B-cells that are donated by convalescent patients following Covid-19 infection.

Immune Response 264

Immune Response Antibody Vaccine Vaccination 264

Bio Pharma Dive

JUNE 16, 2023

The approval of Columvi adds another “bispecific antibody” to the market, highlighting the fast research progress for drugs that target two proteins rather than one.

FDA Approval 177

FDA Approval Drugs Protein Antibody 177

pharmaphorum

JULY 19, 2024

Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its blockbuster credentials.The remarkable renaissance for the BCMA-directed antibody-drug conjugate is supported by a pair of phase 3 trials that could not only support (..)

Marketing 104

Marketing Antibody Trials Drugs 104

Fierce Pharma

JULY 11, 2024

Alzheimer’s disease marketing at Eli Lilly, said during a recent interview.

FDA Approval 111

FDA Approval Marketing Antibody 111

Pharmaceutical Technology

SEPTEMBER 13, 2022

Gilead’s Trodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate (ADC), with a potent topoisomerase I inhibitor payload. As Trodelvy will have the first-in-class advantage in the HER2-negative setting, dato-DXd would have to demonstrate superior efficacy to dominate this market.

HR 162

HR Marketing Hormones FDA Approval 162

Pharmaceutical Technology

JANUARY 27, 2023

All three treatments are monoclonal antibodies. While the occurrence and severity of side effects for Briumvi is comparable to other monoclonal antibodies available on the market, its approval still brings positive news for MS patients, due to its good efficacy in reducing disease progression.

Marketing 130

Marketing Antibody Clinical Trials Clinical Trials 130

Bio Pharma Dive

FEBRUARY 14, 2023

The British drugmaker will retain an interest in COVID antibody drug sotrovimab, which was withdrawn from the U.S. market, and a second treatment still in early-stage trials.

Antibody 169

Antibody Trials Marketing Drugs 169